January 2022 Publications
- An Update on Tuberculosis Vaccines. Gopalaswamy R, Subbian S. Methods Mol Biol. 2022. doi: 10.1007/978-1-0716-1884-4_20.
- 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, Mandalakas AM. Lancet Infect Dis. 2022 Jan. doi: 10.1016/S1473-3099(21)00403-5. Epub 2021 Sep 7.
- Revisiting the Principles of Designing a Vaccine. Zutshi S, Kumar S, Chauhan P, Saha B. Methods Mol Biol. 2022. doi: 10.1007/978-1-0716-1884-4_3.
- Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update. Brito AC, Oliveira CMM, Unger DA, Bittencourt MJS. An Bras Dermatol. 2022 Jan 4. doi: 10.1016/j.abd.2021.07.004. Online ahead of print.
- Design of a peptide-based vaccine from late stage specific immunogenic cross-reactive antigens of PE/PPE proteins of Mycobacterium tuberculosis. Medha, Priyanka, Sharma S, Sharma M. Eur J Pharm Sci. 2022 Jan 1. doi: 10.1016/j.ejps.2021.106051. Epub 2021 Oct 29.
- Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. Jeyanathan M, Fritz DK, Afkhami S, Aguirre E, Howie KJ, Zganiacz A, Dvorkin-Gheva A, Thompson MR, Silver R, Cusack RP, Lichty BD, O’Byrne PM, Kolb M, MedinaMFC, Dolovich MB, Satia I, Gauvreau GM, Xing Z, Smaill F. JCI Insight. 2022 Jan 6. doi:10.1172/jci.insight.155655. Online ahead of print.
- Construction of Novel Live Genetically Modified BCG Vaccine Candidates Using Recombineering Tools. Flores-Valdez MA, Aceves-Sánchez MJ. Methods Mol Biol.2022. doi: 10.1007/978-1-0716-1884-4_19.
- Computational Mining and Characterization of Hypothetical Proteins of Mycobacterium bovis Toward the Identification of Probable Vaccine Candidates. Ganguly B. Methods Mol Biol. 2022. doi: 10.1007/978-1-0716-1892-9_24.
- Challenges for Vaccinologists in the First Half of the Twenty-First Century. Thomas S, Abraham A, Callaghan PJ, Rappuoli R. Methods Mol Biol. 2022.doi: 10.1007/978-1-0716-1884-4_1.
- Immunological Assessment of Lung Responses to Inhalational Lipoprotein Vaccines Against Bacterial Pathogens. Ashhurst AS, Hanna CC, Payne RJ, Britton WJ. Methods Mol Biol. 2022. doi: 10.1007/978-1-0716-1900-1_16.
- Considering human challenge trials for tuberculosis vaccine development. Kleinwaks G, Schmit V, Morrison J. Vaccine. 2022 Jan 21. doi: 10.1016/j.vaccine.2021.11.024. Epub 2021 Dec 15.
- Innovative vaccine approaches-a Keystone Symposia report. Cable J, Rappuoli R, Klemm EJ, Kang G, Mutreja A, Wright GJ, Pizza M, Castro SA, Hoffmann JP, Alter G, Carfi A, Pollard AJ, Krammer F, Gupta RK, Wagner CE, Machado V, Modjarrad K, Corey L, B Gilbert P, Dougan G, Lurie N, Bjorkman PJ, Chiu C, Nemes E, Gordon SB, Steer AC, Rudel T, Blish CA, Sandberg JT, Brennan K, Klugman KP, Stuart LM, Madhi SA, Karp CL. Ann N Y Acad Sci. 2022 Jan 14. doi: 10.1111/nyas.14739. Online ahead of print.
- Dissecting the Mycobacterium bovis BCG Response to Macrophage Infection to Help Prioritize Targets for Anti-Tuberculosis Drug and Vaccine Discovery. Medley J, Goff A, Bettencourt PJG, Dare M, Cole L, Cantillon D, Waddell SJ. Vaccines (Basel). 2022 Jan 13. doi: 10.3390/vaccines10010113.
- Vaccination against tuberculosis, polio and hepatitis B at birth in Podor health district, Northern Senegal: cross-sectional study of vaccination coverage and its associated factors. Bassoum O, Sougou NM, Ba MF, Anne M, Bocoum M, Dieye A, Sokhna C, Tal-Dia A. BMC Public Health. 2022 Jan 15. doi: 10.1186/s12889-022-12535-z.
- Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection. Pi J, Zhang Z, Yang E, Chen L, Zeng L, Chen Y, Wang R, Huang D, Fan S, Lin W, Shen H, Xu JF, Zeng G, Shen L. J Nanobiotechnology. 2022 Jan 15. doi: 10.1186/s12951-021-01234-3.
- CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. James CA, Xu Y, Aguilar MS, Jing L, Layton ED, Gilleron M, Minnaard AJ, Scriba TJ, Day CL, Warren EH, Koelle DM, Seshadri C. Nat Commun. 2022 Jan 10. doi: 10.1038/s41467-021-27764-w.
- Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17-Dependent Protection against Mycobacterium tuberculosis Infection. Jong RM, Van Dis E, Berry SB, Nguyenla X, Baltodano A, Pastenkos G, Xu C, Fox D, Yosef N, McWhirter SM, Stanley SA. J Immunol. 2022 Jan 15. doi: 10.4049/jimmunol.2100029. Epub 2021 Dec 29.
- Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis. Bastos RG, Alzan HF, Rathinasamy VA, Cooke BM, Dellagostin OA, Barletta RG, Suarez CE. Vaccines (Basel). 2022 Jan 14. doi: 10.3390/vaccines10010123.
- Bacille Calmette-Guérin Skin Reaction Predicts Enhanced Mycobacteria-Specific T Cell Responses in Infants. Pittet LF, Fritschi N, Tebruegge M, Dutta B, Donath S, Messina NL, Casalaz D, Hanekom WA, Britton WJ, Robins-Browne R, Curtis N, Ritz N; BCG Immune Response Study (BIRS) group. Am J Respir Crit Care Med. 2022 Jan 10. doi: 10.1164/rccm.202108-1892OC. Online ahead of print..
- The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study. Fack C, Wood R, Hatherill M, Cobelens F, Hermans S. Vaccine. 2022 Jan 21. doi: 10.1016/j.vaccine.2021.11.043. Epub 2021 Dec 3.
- BCG vaccination induces cross-protective immunity against pathogenic microorganisms. Soto JA, Gálvez NMS, Andrade CA, Ramírez MA, Riedel CA, Kalergis AM, Bueno SM. Trends Immunol. 2022 Jan 21. doi: 10.1016/j.it.2021.12.006. Online ahead of print..